Science Corp. raised $230 million in an oversubscribed series C financing round to commercialize its Prima brain-computer interface (BCI) retinal implant and to advance other pipeline programs into the clinic. The investment brings the company’s total funding, since founding in 2021, to approximately $490 million and shows investors growing appetite for BCI technologies.
Biopharma and med-tech companies raising money in public or private financings, including: Antiverse, Beken, Informuta, Maia, Modular, Poplar, Prolium, Xsensio.
Polares Medical SA raised $50 million in a series C financing round for Mrace, its posterior leaflet replacement system designed to treat mitral regurgitation.
Biopharma and med-tech companies raising money in public or private financings, including: Beone, Defence, Edison, Jazz, Royalty, Sharp, Telo Genomics, Zymeworks.
Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.
Biopharma and med-tech companies raising money in public or private financings, including: Abram, Bicara, Breezebio, Octapharma, Respiree, Trinity, Zura.
At Biocom’s Global Partnering and Investor Conference, venture capitalists (VCs) on multiple panels offered their thoughts on the state of venture investing and offered advice for startups interested in securing funding. Sentiment for early stage investment was somewhat mixed, but trended negative as VCs acknowledged that it’s a tough environment in which to raise capital.
Biopharma and med-tech companies raising money in public or private financings, including: Abbott, Allurion, Alveus, Brainomix, Centauri, Exact Sciences, Salspera, Slate, Tandem Diabetes.
RSS
